Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with ...
Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of 31 December 2024: Cash: € 349,630.55 Number of shares ...
Inventiva est une société biopharmaceutique spécialisée dans la recherche et développement de petites molécules administrées par voie orale pour le traitement de patients atteints de la ...
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with ...
Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of 31 December 2024: At the last half-year report as of 30 ...
24/01 FW Kepler Cheuvreux relève le prix cible pour Investor à 357 SEK (346) et réaffirme son intention de l'acheter. 24/01 FW DNB relève l'objectif de prix pour Investor à 345 SEK (330 ...
Kepler Cheuvreux analyst Conor O’Shea upgraded WPP (WPP) to Buy from Hold with a price target of 935 GBp, up from 845 GBp. The firm says the shares are near six month lows while the the company ...
On Jan. 20, President Donald Trump was sworn in as the 47th President of the United States. On his first day in office, he took 42 presidential actions, including signing 26 executive orders. In the ...
On Wednesday, Kepler Cheuvreux initiated coverage on Nexity (EPA:NEXI) SA (NXI:FP), a prominent player in the French real estate market, assigning a Hold rating to the company's shares. The research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback